Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för Gedatolisib. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

12 träffar

Bibliografisk träff 2024-04-25

Design, Synthesis, Formulation, and Bioevaluation of Trisubstituted Triazines as Highly Selective mTOR Inhibitors for the Treatment of Human Breast Cancer.

Sun Q, Chu Y, Zhang N, Chen R, Wang L, Wu J, Dong Y, Li H, Wang L, Tang L, Zhan C, Zhang JQ.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.4c00173

Bibliografisk träff 2024-01-23

Targeting autophagy drug discovery: Targets, indications and development trends.

Jiang M, Wu W, Xiong Z, Yu X, Ye Z, Wu Z.

Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2023.116117

Bibliografisk träff 2023-12-31

Advancements in dual-target inhibitors of PI3K for tumor therapy: Clinical progress, development strategies, prospects.

Hu J, Fu S, Zhan Z, Zhang J.

Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2023.116109

Bibliografisk träff 2021-12-20

Synthesis and bioevaluation of diaryl urea derivatives as potential antitumor agents for the treatment of human colorectal cancer.

Wu CF, Wang QC, Chen R, Zhou HL, Wu TT, Du Y, Zhang NN, Zhang HM, Fan ZY, Wang LL, Hu CJ, Sang ZP, Li HL, Wang L, Tang L, Zhang JQ.

Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2021.114055

Bibliografisk träff 2021-12-04

Molecular design of dual inhibitors of PI3K and potential molecular target of cancer for its treatment: A review.

Wang Y, Tortorella M.

Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2021.114039

Bibliografisk träff 2021-01-06

Discovery of novel 1,3,5-triazine derivatives as potent inhibitor of cervical cancer via dual inhibition of PI3K/mTOR.

Hu J, Zhang Y, Tang N, Lu Y, Guo P, Huang Z.

Bioorg Med Chem · journal article · DOI 10.1016/j.bmc.2021.115997

Bibliografisk träff 2017-12-20

Design of Small Molecule Autophagy Modulators: A Promising Druggable Strategy.

He S, Li Q, Jiang X, Lu X, Feng F, Qu W, Chen Y, Sun H.

J Med Chem · research support, non-u.s. gov't; review; journal article · DOI 10.1021/acs.jmedchem.7b01019

Bibliografisk träff 2017-12-01

The target landscape of clinical kinase drugs.

Klaeger S, Heinzlmeir S, Wilhelm M, Polzer H, Vick B, Koenig PA, Reinecke M, Ruprecht B, Petzoldt S, Meng C, Zecha J, Reiter K, Qiao H, Helm D, Koch H, Schoof M, Canevari G, Casale E, Depaolini SR, Feuchtinger A, Wu Z, Schmidt T, Rueckert L, Becker W, Huenges J, Garz AK, Gohlke BO, Zolg DP, Kayser G, Vooder T, Preissner R, Hahne H, Tõnisson N, Kramer K, Götze K, Bassermann F, Schlegl J, Ehrlich HC, Aiche S, Walch A, Greif PA, Schneider S, Felder ER, Ruland J, Médard G, Jeremias I, Spiekermann K, Kuster B.

Science · research support, non-u.s. gov't; research-article; journal article · DOI 10.1126/science.aan4368

Bibliografisk träff 2017-09-01

5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.

Beaufils F, Cmiljanovic N, Cmiljanovic V, Bohnacker T, Melone A, Marone R, Jackson E, Zhang X, Sele A, Borsari C, Mestan J, Hebeisen P, Hillmann P, Giese B, Zvelebil M, Fabbro D, Williams RL, Rageot D, Wymann MP.

J Med Chem · research-article; journal article · DOI 10.1021/acs.jmedchem.7b00930

Bibliografisk träff 2014-12-05

Phosphatidylinositol 3-Kinase (PI3K) and phosphatidylinositol 3-kinase-related kinase (PIKK) inhibitors: importance of the morpholine ring.

Andrs M, Korabecny J, Jun D, Hodny Z, Bartek J, Kuca K.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/jm501026z

Bibliografisk träff 2011-06-21

Identification of 2-oxatriazines as highly potent pan-PI3K/mTOR dual inhibitors.

Dehnhardt CM, Venkatesan AM, Chen Z, Delos-Santos E, Ayral-Kaloustian S, Brooijmans N, Yu K, Hollander I, Feldberg L, Lucas J, Mallon R.

Bioorg Med Chem Lett · journal article · DOI 10.1016/j.bmcl.2011.06.063

Bibliografisk träff 2010-03-01

Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor.

Venkatesan AM, Dehnhardt CM, Delos Santos E, Chen Z, Dos Santos O, Ayral-Kaloustian S, Khafizova G, Brooijmans N, Mallon R, Hollander I, Feldberg L, Lucas J, Yu K, Gibbons J, Abraham RT, Chaudhary I, Mansour TS.

J Med Chem · journal article · DOI 10.1021/jm901830p